Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Accelerate Diagnostics Inc. Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Accelerate Diagnostics Inc (AXDX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 37,049,299 | $18,524,650 | +51% | 11.12% | |
| 2. | Armistice Capital Steven Boyd | 1,879,227 | $1,317,338 | -10% | 0.02% |
| 3. | Birchview Capital Matthew Strobeck | 325,239 | $227,992 | 0.2% | |
| 4. | Renaissance Technologies Jim Simons | 64,200 | $45,004 | -41% | 0% |
| 5. | Citadel Investment Group Ken Griffin | 23,451 | $16,439 | -34% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.57 | 200,000 | $314,000.00 | 653,224 | 2024-12-03 | Filing | |
| $0.00 | 100,000 | $0.00 | 120,682 | 2024-01-23 | Filing | |
| $0.00 | 13,333 | $0.00 | 20,927 | 2024-01-23 | Filing | |
| $0.00 | 16,666 | $0.00 | 24,260 | 2024-01-23 | Filing | |
| $0.00 | 16,666 | $0.00 | 453,224 | 2024-01-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.65 | 25,343 | $16,472.95 | 191,374 | 2025-04-04 | Filing | |
| $0.65 | 1,523 | $989.95 | 84,803 | 2025-04-04 | Filing | |
| $0.71 | 6,816 | $4,839.36 | 64,568 | 2025-04-01 | Filing | |
| $1.09 | 535 | $583.15 | 51,384 | 2025-02-26 | Filing | |
| $1.35 | 485 | $654.75 | 163,434 | 2025-02-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,292,574 | $1,317,029 | 0.42% | |
| 2. | 2,096,272 | $1,251,068 | 0.24% | |
| 3. | 5,283,122 | $822,363 | 0.01% | |
| 4. | 853,036 | $597,978 | 0.07% | |
| 5. | 478,093 | $335,143 | 0% |
News See All
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q2 2024 Earnings Call Transcript
Operator: Good day. And welcome to the Accelerate Diagnostics Incorporated Second Quarter 2024 Results Conference Call. All participants will be in a listen-only mode.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q1 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Accelerate Diagnostics Incorporated. First Quarter 2024 Results Conference Call. All participants will be in a listen only mode.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q4 2023 Earnings Call Transcript
Accelerate Diagnostics, Inc. misses on earnings expectations. Reported EPS is $-0.89 EPS, expectations were $-0.62. Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2023 Earnings Call Transcript
Operator: Good day, and welcome to the Accelerate Diagnostics, Inc. 2023 Third Quarter Results Conference Call. All participant’s will be in listen-only mode.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q2 2023 Earnings Call Transcript
Operator: Good day, and welcome to the Accelerate Diagnostics, Inc. 2023 Q2 Results Conference Call. [Operator Instructions].
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q1 2023 Earnings Call Transcript
Operator: Good day, and welcome to the Accelerate Diagnostics Incorporated 2023 Q1 Results Conference Call. All participants will be in listen-only mode.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Accelerate Diagnostics Fourth Quarter 2022 Earnings Conference Call. Please note, this event is being recorded.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2022 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Accelerate Diagnostics Inc. Third Quarter 2022 Earnings Call. . I would now like to turn the conference over to Mr.
5 Biotech Stocks to Buy According to Matthew Strobeck's Birchview Capital
In this article, we discuss 5 biotech stocks to buy according to Matthew Strobeck's Birchview Capital.
Billionaire Hedge Funds
